IRIS Accounts Production v24.3.0.553 06695129 Board of Directors Board of Directors 1.4.23 31.3.24 31.3.24 0 0 false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh066951292023-03-31066951292024-03-31066951292023-04-012024-03-31066951292022-03-31066951292022-04-012023-03-31066951292023-03-3106695129ns15:EnglandWales2023-04-012024-03-3106695129ns14:PoundSterling2023-04-012024-03-3106695129ns10:Director12023-04-012024-03-3106695129ns10:Director22023-04-012024-03-3106695129ns10:PrivateLimitedCompanyLtd2023-04-012024-03-3106695129ns10:SmallEntities2023-04-012024-03-3106695129ns10:AuditExempt-NoAccountantsReport2023-04-012024-03-3106695129ns10:SmallCompaniesRegimeForDirectorsReport2023-04-012024-03-3106695129ns10:SmallCompaniesRegimeForAccounts2023-04-012024-03-3106695129ns10:FullAccounts2023-04-012024-03-3106695129ns10:RegisteredOffice2023-04-012024-03-3106695129ns5:CurrentFinancialInstruments2024-03-3106695129ns5:CurrentFinancialInstruments2023-03-3106695129ns5:Non-currentFinancialInstruments2024-03-3106695129ns5:Non-currentFinancialInstruments2023-03-3106695129ns5:ShareCapital2024-03-3106695129ns5:ShareCapital2023-03-3106695129ns5:RetainedEarningsAccumulatedLosses2024-03-3106695129ns5:RetainedEarningsAccumulatedLosses2023-03-3106695129ns5:LandBuildings2023-04-012024-03-3106695129ns5:LandBuildings2023-03-3106695129ns5:LandBuildings2024-03-3106695129ns5:LandBuildings2023-03-3106695129ns5:Secured2024-03-3106695129ns5:Secured2023-03-31
REGISTERED NUMBER: 06695129 (England and Wales)



















UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2024

FOR

JMEDICAL LIMITED

JMEDICAL LIMITED (REGISTERED NUMBER: 06695129)






CONTENTS OF THE FINANCIAL STATEMENTS
for the Year Ended 31 MARCH 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


JMEDICAL LIMITED

COMPANY INFORMATION
for the Year Ended 31 MARCH 2024







DIRECTORS: Dr K S Kirkbride-Jamu
Dr A Field





REGISTERED OFFICE: 48 The Glebe
Clapham
Bedford
Bedfordshire
MK41 6GA





REGISTERED NUMBER: 06695129 (England and Wales)





ACCOUNTANTS: Foxley Kingham Medical
260 - 270 Butterfield
Great Marlings
Luton
Bedfordshire
LU2 8DL

JMEDICAL LIMITED (REGISTERED NUMBER: 06695129)

BALANCE SHEET
31 MARCH 2024

2024 2023
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 2,159,643 2,159,643

CURRENT ASSETS
Cash at bank 91,766 86,533

CREDITORS
Amounts falling due within one year 5 163,610 149,726
NET CURRENT LIABILITIES (71,844 ) (63,193 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

2,087,799

2,096,450

CREDITORS
Amounts falling due after more than one
year

6

1,817,238

1,865,103
NET ASSETS 270,561 231,347

CAPITAL AND RESERVES
Called up share capital 150 150
Retained earnings 270,411 231,197
SHAREHOLDERS' FUNDS 270,561 231,347

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

JMEDICAL LIMITED (REGISTERED NUMBER: 06695129)

BALANCE SHEET - continued
31 MARCH 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 14 November 2024 and were signed on its behalf by:




Dr K S Kirkbride-Jamu - Director



Dr A Field - Director


JMEDICAL LIMITED (REGISTERED NUMBER: 06695129)

NOTES TO THE FINANCIAL STATEMENTS
for the Year Ended 31 MARCH 2024

1. STATUTORY INFORMATION

Jmedical Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Land and buildings - in accordance with the property

The land and buildings are being depreciated to their estimated residual value over their deemed useful economic life. The directors believe the residual value to be at least the current carrying value in these accounts and therefore any depreciation would be negligible. The maintenance costs are charged to the profit and loss account in the year incurred. The directors review the estimated residual value at the end of each accounting period.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Other operating income
Other operating income represents rental income receivable, excluding value added tax.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was NIL (2023 - NIL).

JMEDICAL LIMITED (REGISTERED NUMBER: 06695129)

NOTES TO THE FINANCIAL STATEMENTS - continued
for the Year Ended 31 MARCH 2024

4. TANGIBLE FIXED ASSETS
Land and
buildings
£   
COST
At 1 April 2023
and 31 March 2024 2,159,643
NET BOOK VALUE
At 31 March 2024 2,159,643
At 31 March 2023 2,159,643

5. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Bank loans and overdrafts 47,865 44,925
Taxation and social security 5,570 5,521
Other creditors 110,175 99,280
163,610 149,726

6. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE
YEAR
2024 2023
£    £   
Bank loans 1,817,238 1,865,103

Amounts falling due in more than five years:

Repayable by instalments
Bank loans more than 5 years 1,592,333 1,654,013

7. SECURED DEBTS

The following secured debts are included within creditors:

2024 2023
£    £   
Bank loans 1,865,103 1,910,028

The company's bank holds a fixed and floating charge over the company's assets as security for the bank loan.

8. ULTIMATE CONTROLLING PARTY

The company is controlled by the directors by virtue of their holding of the company's issued share capital.